FRANKLIN LAKES, N.J., Aug. 16, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Jeffrey W. Henderson has been elected to the company's board of directors.
Henderson, 53, is the non-executive chairman of the board of Qualcomm, Inc. and serves on the board of directors at FibroGen, Inc. and Halozyme Therapeutics, Inc. as well as serving as an advisory director to Berkshire Partners LLC. Prior to these roles, he served for nearly 10 years as chief financial officer of Cardinal Health, a $137 billion global health care services and products company, and also oversaw the company's China and Canada operations. Prior to Cardinal Health, Henderson spent seven years at Eli Lilly & Co. where he was vice president and corporate controller, as well as president and general manager of its Canada operations. He also spent 10 years at General Motors Corp. holding a variety of leadership roles in the U.S., Canada, the United Kingdom and Singapore.
"Jeff has deep health care experience that will be of great value to BD as we continue to drive our strategy to provide innovative solutions to improve both the treatment of disease for patients and the process of care for health care providers across all regions of the world," said Vincent A. Forlenza, chairman and CEO of BD. "His financial, operational and international leadership at large, multinational companies brings highly complementary expertise to BD and our board of directors."
Henderson received a Bachelor of Science degree in electrical engineering from Kettering University and a Master of Business Administration degree from Harvard Graduate School of Business Administration.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
SOURCE BD (Becton, Dickinson and Company)